KAI Pharmaceuticals - Ownership and Business Overview

Life ScienceCompany

KAI Pharmaceuticals Ownership

Who owns KAI Pharmaceuticals?

KAI Pharmaceuticals is owned by Amgen. It was acquired on April 10, 2012.

KAI Pharmaceuticals Business Overview

Where is KAI Pharmaceuticals headquartered?

KAI Pharmaceuticals is headquartered in South San Francisco, California.

What sector is KAI Pharmaceuticals in?

KAI Pharmaceuticals is a life science company.

When was KAI Pharmaceuticals founded?

KAI Pharmaceuticals was founded in 2002.

Life Science M&A Summary in 2012

Out of 60 sectors in the Mergr database, life science ranked 18 in number of deals in 2012. The largest life science acquisition in 2012 was Amylin Pharmaceuticals - which was acquired by Bristol-Myers Squibb for $5.3B.

Join Mergr to view all 124 acquisitions of life science companies in 2012, including 18 acquisitions by private equity firms, and 106 by strategics.

KAI Pharmaceuticals, Inc.

270 Littlefield Avenue,
South San Francisco, California 94080
United States,
(650)244-1100

KAI Pharmaceuticals is a life science company based in South San Francisco. KAI's lead product candidate KAI-4169 is a novel agent being studied initially for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. KAI has previously reported compelling Phase 2a clinical results for KAI-4169 in this indication. KAI-4169 is administered intravenously at the same time the patient is undergoing dialysis.


 Subscribe to unlock this and 201,688
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.5K Private Equity Firms
  • 193K M&A Transactions
  • 197K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 75K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.